Navigation Links
Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
Date:9/1/2009

CALGARY, Sept. 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 32nd U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.

"This U.S. patent expands our intellectual property portfolio regarding oncolytic viruses, in addition to reovirus, that can be modified to grow selectively in Ras-mediated cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Including the patent issued today, Oncolytics has now secured five U.S. patents covering the use of other oncolytic viruses to treat Ras-mediated cancers. Patents covering similar subject matter have been granted in other jurisdictions as well."

    U.S. Patents issued previously include:

    -   U.S. Patent # 6,596,268, which covers adenoviruses modified in the
        VAI gene;

    -   U.S. Patent # 7,344,711, which covers adenoviruses modified in the
        VAI and VAII genes;

    -   U.S. Patent # 6,649,157, which covers herpes simplex virus (HSV)
        mutated in the ?134.5 gene; and

    -   U.S. Patent # 7,252,817, which covers modified HSV, where the ?
        134.5 gene is lacking, inhibited or mutated such that PKR activation
        is not blocked.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of ... Desktop modules to its flagship X-Win32 PC X server. The new modules enable ... user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy the ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... The MIT ... textile design, the bioLogic team explored how bacterial properties can be applied to fabric ... using Natto bacteria, which move in response to humidity change. The team harvested Natto ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... in spinal surgical procedures, today announced the completion of a significant transaction and ... current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a two ... into a viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders ... and mentor in the Denver area business community, shared his top fundamental learnings ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... LONDON , March 17, 2016 ... market intelligence, forecasts the global biometrics market will ... an impressive 118% increase from 2015. Consumer electronics, ... with embedded fingerprint sensors anticipated to reach two ... Dimitrios Pavlakis , Research Analyst ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
Breaking Biology News(10 mins):